603127 昭衍新药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.7530.9064.82314.02413.335
总资产报酬率 ROA (%)0.6460.7633.89411.36710.474
投入资产回报率 ROIC (%)0.6680.7904.08911.93211.017

边际利润分析
销售毛利率 (%)24.02728.42842.61747.89848.733
营业利润率 (%)11.9445.17021.33854.04142.388
息税前利润/营业总收入 (%)6.3870.21114.97447.85441.067
净利润/营业总收入 (%)9.1143.45616.47647.32036.686

收益指标分析
经营活动净收益/利润总额(%)1.474244.702148.82668.48466.931
价值变动净收益/利润总额(%)149.969-87.503-46.55629.24127.224
营业外收支净额/利润总额(%)0.330-0.296-0.0291.158-0.138

偿债能力分析
流动比率 (X)4.5244.5304.8543.2154.789
速动比率 (X)3.1863.1993.5842.0254.212
资产负债率 (%)14.44514.01617.41420.97016.313
带息债务/全部投入资本 (%)9.2818.79211.43512.76211.421
股东权益/带息债务 (%)953.8311,011.605749.269657.404757.156
股东权益/负债合计 (%)592.277613.442474.155376.548512.423
利息保障倍数 (X)-1.141-0.043-2.355-7.016-32.515

营运能力分析
应收账款周转天数 (天)45.81234.53030.71024.36923.317
存货周转天数 (天)538.566416.385535.589441.019256.218